Related Experiment Video
Updated: May 4, 2026
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Using Electronic Patient-Reported Outcome Measures for Patients With Metastatic Renal Cell Carcinoma: A Narrative
Lucie Minot1, Vincent Javaugue2, Marlène Arbutina3
1Lucie Minot.
Background:
The variety of therapeutic associations in first-line treatment of advanced and metastatic renal cell cancer (mRCC) illustrates the complexity of toxicity management that can affect patients' health-related quality of life (HRQOL). Electronic monitoring applications have become part of the daily practice of providers in following up with people with cancer.
Objectives:
This article offers perspectives for electronic patient-reported outcome measures (ePROMs) in clinical practice to enhance symptom management and HRQOL for patients with mRCC.
Methods:
A narrative review combines the results of searches conducted on MEDLINE®, Embase®, and Cochrane Library for articles that identify therapeutic combinations used in treating mRCC, extract HRQOL data, and evaluate the benefits of ePROMs.
Findings:
ePROMs can be adapted to the toxicity and symptom specificities encountered in patients with mRCC undergoing front-line treatment. Combined with multidimensional HRQOL indicators, these tools can improve symptom management and provide early support adapted to the patient's needs.
More Related Videos
Related Concept Videos
01:30Methods of Documentation VII: EMR
01:24Kaplan-Meier Approach